Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Devyser Diagnostics

63.00 SEK+0.32 %19.11, 16.04
Less than 1K followers

DVYSR

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.32 %
+26.00 %
+4.30 %
-30.08 %
-44.83 %
-42.20 %
-6.53 %
-
-29.21 %

Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Årsta, Sweden.

Read more
Market cap
1.06B SEK
Turnover
636.28K SEK
Revenue
250.5M
EBIT %
4.03 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
16.2
2027

Annual report '26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release03.11.2026, 07.30

Devyser Diagnostics AB publishes quarterly report for the period July to September 2026

Devyser Diagnostics
Press release27.10.2026, 14.00

Devyser extends its transplant test to heart and lung patients

Devyser Diagnostics
Press release22.10.2026, 10.00

Invitation to Devyser’s Q3 2026 results presentation

Devyser Diagnostics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release21.10.2026, 14.00

Devyser wins tender in Italy worth approximately SEK 5.7 million – doubling test volumes compared with previous agreement

Devyser Diagnostics
Press release31.08.2026, 10.00

Devyser appoints Torben Thölix as the new Chief Commercial Officer

Devyser Diagnostics
Press release06.08.2026, 08.00

Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy

Devyser Diagnostics
Devyser Diagnostics, Audiocast, Q2'26
Webcast20.07.2026, 09.00

Devyser Diagnostics, Audiocast, Q2'26

Devyser Diagnostics
Regulatory press release20.07.2026, 07.30

Devyser Diagnostics AB publishes quarterly report for the period April to June 2026

Devyser Diagnostics
Press release16.07.2026, 08.00

Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring

Devyser Diagnostics
Press release14.07.2026, 10.00

Invitation to audiocast for Devyser’s Q2 report 2026

Devyser Diagnostics
Regulatory press release02.07.2026, 20.50

Sales in the second quarter of 2026 weaker than expected

Devyser Diagnostics
Press release25.06.2026, 10.00

Devyser secures SEK 8.9M five-year tender and strengthens Italian position

Devyser Diagnostics
Regulatory press release22.05.2026, 08.30

Devyser strengthens its executive management team – Niklas Axelsson appointed new CFO and Sabina Berlin transitions to a new role within the company

Devyser Diagnostics
Regulatory press release06.05.2026, 13.30

Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 6 May 2026

Devyser Diagnostics
Devyser Diagnostics, Audiocast, Q1'26
Webcast27.04.2026, 11.00

Devyser Diagnostics, Audiocast, Q1'26

Devyser Diagnostics
Regulatory press release27.04.2026, 09.00

Devyser Diagnostics AB publishes quarterly report for the period January to March 2026

Devyser Diagnostics
Press release22.04.2026, 09.00

Invitation to audiocast for Devyser’s Q1 report 2026

Devyser Diagnostics
Press release07.04.2026, 07.50

Devyser announces that Chief Commercial Officer will leave the company

Devyser Diagnostics
Regulatory press release01.04.2026, 10.15

Devyser completes acquisition of CyberGene AB and carries out issue of compensation shares

Devyser Diagnostics
Press release25.03.2026, 10.00

Devyser publishes annual report for 2025

Devyser Diagnostics